Clinical Trials Logo

Hypertension clinical trials

View clinical trials related to Hypertension.

Filter by:

NCT ID: NCT00302211 Terminated - Clinical trials for Pulmonary Hypertension

The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension

VISION
Start date: February 1, 2006
Phase: Phase 3
Study type: Interventional

The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary arterial hypertension (PAH). The study will also examine whether patients on sildenafil can reduce the number of iloprost inhalations from the approved 6 doses per day to 4 doses per day.

NCT ID: NCT00274105 Terminated - Hypertension Clinical Trials

SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients

Start date: March 2001
Phase: Phase 4
Study type: Interventional

The aim of this trial is to evaluate the efficacy and safety of telmisartan 80 mg administered once daily in patients with documented coronary artery disease (CAD) and a probably cardiovascular risk profile concerning the amelioration of structural alterations and endothelial function. The primary objective of this trial is to evaluate the efficacy in particular with regard to the percentage change of atheroma volume in the femoral artery.The secondary objective is to evaluate the change in the plaque size- assessed by intravascular ultrasound, the increase in Flow Dependent Dilation provoked by intraarterial infusion of three increasing concentrations of Acetylcholine, and the change in seated systolic blood pressure. Endothelial dysfunction is a primary event in atherogenesis and all known cardiovascular risk factors have been associated with endothelial dysfunction before atherosclerotic vascular disease manifests itself clinically. Pivotal to endothelial dysfunction is a disturbance in the function of endothelium-derived nitric oxide (NO). Recently, it could be shown that acute and chronic angiotensin-1 receptor antagonism reversed endothelial dysfunction in atherosclerosis. In experimental atherosclerosis, AT1 receptor blockade appears to have protective effects. Respective potential mechanisms include the prevention of endothelial injury, the augmentation of NO activity, the inhibition of lipid peroxidation and an antiproliferative effect. These findings together with the most recent data that losartan improves endothelial function and NO activity suggest that AT1 receptor antagonism may also be antiatherogenic in patients with atherosclerosis. Angiotensin II influences smooth muscle cell migration, hyperplasia, and hypertrophy. Angiotensin II also enhances production of local superoxide anion, which will inactivate nitric oxide. Inhibition of these reactions by the AT1-Blocker telmisartan may therefore interfere with atherosclerotic plaque formation.

NCT ID: NCT00272961 Terminated - Clinical trials for Resistant Hypertension

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

Start date: January 2006
Phase: Phase 2
Study type: Interventional

The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.

NCT ID: NCT00259714 Terminated - Hypertension Clinical Trials

Dialysate Sodium Individualization in Hemodialysis

Start date: March 2006
Phase: Phase 1
Study type: Interventional

Salt and water excess is an essential mechanism of hypertension. This is particularly relevant to patients with end stage kidney disease (ESKD) on dialysis. We have demonstrated that individualization of the sodium concentration in the dialysate as to match the patient's own serum sodium concentration leads to less thirst, interdialytic weight gain, and better BP control in hypertensive patients. In this study we will evaluate the mechanisms underlying this response by measuring systemic hemodynamics, body volume spaces, and biochemical marker of volume status.

NCT ID: NCT00242645 Terminated - Hypertension Clinical Trials

Computer-Assisted Cancer Risk Behavior Counseling

Start date: June 2004
Phase: Phase 1
Study type: Interventional

To test whether or not giving patients information before their doctor visits changes the care they receive and what type of information is best to give before the doctor visit.

NCT ID: NCT00234260 Terminated - Hypertension Clinical Trials

Family Blood Pressure Program - GENOA (Genetic Epidemiology Network of Atherosclerosis)

Start date: April 1995
Phase: N/A
Study type: Observational

GENOA, the Genetic Epidemiology Network of Arteriopathy, consists of a network of three field centers and biochemical and genetic core labs to study the common polymorphic genetic variations to determine individual differences in blood pressure and essential hypertension in 1,500 sibling pairs in three racial groups. Linkage analyses are performed using an extensive array of candidate genes and anonymous markers throughout the genome.

NCT ID: NCT00208845 Terminated - Clinical trials for Asymptomatic Hypertension

Hypernet- Hypertension Screening

Start date: September 2005
Phase: N/A
Study type: Observational

Identify untreated, asymptomatic hypertension in ER patients

NCT ID: NCT00208221 Terminated - Hypertension Clinical Trials

Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if a dose of ramipril combined with a normal dose of telmisartan 80 mg will be more effective than ramipril 20 mg in reducing microalbuminuria in hypertensive patients with diabetes.

NCT ID: NCT00208104 Terminated - Clinical trials for Essential Hypertension

Motivational Interviewing

Start date: July 2002
Phase: N/A
Study type: Interventional

The purpose of this project is to study ways to make it more likely that patients will take their blood pressure medicine as recommended by their doctors.

NCT ID: NCT00187785 Terminated - Hypertension Clinical Trials

Doctor-Patient Communication in Spanish

Start date: September 2005
Phase: N/A
Study type: Interventional

Does use of a translator or use of less than perfect Spanish diminish provider-patient communication compared to a native speaker.